CCL2 and glioblastoma: Hence, we considered mNOX-E36 to be well suited for the antagonism of CCL2 in the present study, and we used mNOX-E36 to investigate whether resistance to antiangiogenic treatment could be overcome with immunosuppressive therapy that blocked macrophage recruitment in GBM.